Interleukin‐7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren’s Syndrome
Year: 2020
Type: article
Abstract: OBJECTIVE: Primary Sjögren's syndrome (SS) is characterized by a lymphocytic infiltration of salivary glands (SGs) and the presence of an interferon (IFN) signature. SG epithelial cells (SGECs) play an active role in primary SS pathophysiology. We undertook this study to examine the interactions between SGECs and T cells in primary SS and the role of the interleukin-7 (IL-7)/IFN axis. METHODS: Primary cultured SGECs from control subjects and patients with primary SS were stimulated with poly(I-C), IFNα, or IFNγ. T cells were sorted from blood and stimulated with IL-7. CD25 expression was assessed by flow cytometry. SG explants were cultured for 4 days with anti-IL-7 receptor (IL-7R) antagonist antibody (OSE-127), and transcriptomic analysis was performed using the NanoString platform. RESULTS: Serum IL-7 level was increased in patients with primary SS compared to controls and was associated with B cell biomarkers. IL7R expression was decreased in T cells from patients with primary SS compared to controls. SGECs stimulated with poly(I-C), IFNα, or IFNγ secreted IL-7. IL-7 stimulation increased the activation of T cells, as well as IFNγ secretion. Transcriptomic analysis of SG explants showed a correlation between IL7 and IFN expression. Finally, explants cultured with anti-IL-7R antibody showed decreased IFN-stimulated gene expression. CONCLUSION: These results suggest the presence of an IL-7/IFNγ amplification loop involving SGECs and T cells in primary SS. IL-7 was secreted by SGECs stimulated with type I or type II IFN and, in turn, activated T cells that secrete type II IFN. An anti-IL-7R antibody decreased the IFN signature in T cells in primary SS and could be of therapeutic interest.
Source: Arthritis & Rheumatology
DOI: 10.1002/art.41558
Authors: Elodie Rivière, Juliette Pascaud, Alexandre Virone, Anastasia Dupré, Bineta Ly, Audrey Paoletti, Raphaèle Seror, Nicolas Tchitchek, Michael Mingueneau, Nikaïa Smith, Darragh Duffy, Lydie Cassard, Nathalie Chaput, Sabrina Pengam, Vanessa Gauttier, Nicolas Poirier, Xavier Mariette, Gaetane Nocturne
Institutions: Inserm, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, CEA Paris-Saclay, Biogen (United States), Institut Pasteur, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse, OSE Immunotherapeutics (France)
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: Biogen, European Federation of Pharmaceutical Industries and Associations, European Commission, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Institut National Du Cancer, Université Paris-Sud, Direction Générale de l’offre de Soins, Assistance publique-Hôpitaux de Paris, Innovative Medicines Initiative, Servier, Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique
Awards: G1974958266, G2874138555, G434337789, SOCRATE 2.0: Stratified oncology cell DNA repair and tumor elimination 2.0, NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients, G7561205451, G7665619280, Research Laboratory on Drugs and Therapeutic Innovation, G801932575, G8618755740
OpenAlex ID: W3093392005
